Interventions for alleviating cancer-related dyspnea: A systematic review and meta-analysis

Acta Oncologica

Volumn 51, Issue 8, 2012, Pages 996-1008

  Ben Aharon, Irit ^a,b   Gafter Gvili, Anat ^a,b   Leibovici, Leonard ^a,b   Stemmer, Salomon M ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

FUROSEMIDE; HEMOGLOBIN; HYDROMORPHONE; MIDAZOLAM; MORPHINE; OXYGEN; PLACEBO;

CANCER PATIENT; CANCER RELATED DYSPNEA; COMPARATIVE STUDY; DYSPNEA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOXIA; OXYGEN SATURATION; OXYGEN THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT FAILURE;

ANALGESICS, OPIOID; BENZODIAZEPINES; DYSPNEA; FUROSEMIDE; HUMANS; NEOPLASMS; OXYGEN; PALLIATIVE CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TERMINAL CARE;

EID: 84867554588     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.709638     Document Type: Review

References (42)

1. Reuben D B, M or V. D yspnea in terminally ill cancer patients. Chest 1986; 89 : 234 - 6 .
2. Burdon JG, P ain MC, R ubinfeld AR, N ana A. C hronic lung diseases and the perception of breathlessness: A clinical perspective. Eur Respir J 1994; 7 : 1342 - 9 .
3. Mercadante S, C asuccio A, F ulfaro F. T he course of symptom frequency and intensity in advanced cancer patients followed at home. J Pain Symptom Manage 2000; 20 : 104 - 12 .
4. Noseda A, C arpiaux JP, M arkstein C, M eyvaert A, d e Maertelaer V. Disabling dyspnoea in patients with advanced disease: Lack of effect of nebulized morphine. Eur Respir J 1997; 10 : 1079 - 83 .
5. Williams C M. D yspnea. C ancer J 2 006; 1 2: 3 65- 73.
6. Bruera E, S ala R, S pruyt O, P almer JL, Z hang T, W illey J. Nebulized versus subcutaneous morphine for patients with cancer dyspnea: A preliminary study. J Pain Symptom Manage 2005; 29 : 613 - 8 .
7. Seow H, B arbera L, S utradhar R, H owell D, D udgeon D, Atzema C, et al. Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol 2011; 29 : 1151 - 8 .
8. Jennings AL, D avies AN, H iggins JP, G ibbs JS, B roadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002; 57 : 939 - 44 .
9. Uronis HE, C urrow DC, M cCrory DC, S amsa GP, Abernethy AP. Oxygen for relief of dyspnoea in mildly- or non-hypoxaemic patients with cancer: A systematic review and meta-analysis. Br J Cancer 2008; 29 : 294 - 9 .
10. Ben-Aharon I, G after-Gvili A, P aul M, L eibovici L, Stemmer SM. Interventions for alleviating cancer- related dyspnea: Systematic review. J Clin Oncol 2008; 26 : 2396 - 404 .
11. Bausewein C, B ooth S, G ysels M, H igginson I. N onpharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. Cochrane Database Syst Rev 2008; 16; 2 .
12. Higgins JPT, G reen S. C ochrane Handbook for System atic Reviews of Interventions Version 5.0. The Cochrane Collaboration; 2008 [cited 2011 Jul 30]. Available from: www.cochrane-handbook.org.
13. DerSimonian R, L aird N. M eta-analysis in clinical trials. Control Clin Trials 1986; 7 : 177 - 88 .
14. Mazzocato C, B uclin T, R apin CH. T he effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: A randomized doubleblind controlled trial. Ann Oncol 1999; 10 : 1511 - 4 .
15. Bruera E, M acEachern T, R ipamonti C, H anson J. S ubcutaneous morphine for dyspnea in cancer patients. Ann Intern Med 1993; 119 : 906 - 7 .
16. Charles MA, R eymond L, I srael F. R elief of incident dyspnea in palliative cancer patients: A pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. J Pain Symptom Manage 2008; 36 : 29 - 38 .
17. Clemens K E, Q uednau I, K laschik E. U se of oxygen and opioids in the palliation of dyspnea in hypoxic and non-hypoxic palliative care patients: A prospective study. Support Care Cancer 2009; 17 : 367-377
18. Davis C, Penn K A 'H ern R, D aniels J, S levin M. S ingle dose randomized controlled trial of nebulised morphine in patients with cancer related breathlessness. Palliat Med 1996; 10 : 64 - 5 .
19. Grimbert D, L ubin O, d e Monte M, V ecellio None L, Perrier M, Carr é P. Dyspnea and morphine aerosols in the palliative care of lung cancer [French]. Rev Mal Respir 2004; 21 : 1091 - 7 .
20. Allard P, L amontagne C, B ernard P, T remblay C. H ow effective are supplementary doses of opioids for dyspnea in terminally ill cancer patients? A randomized continuous sequential clinical trial. J Pain Symptom Manage 1999; 17 : 256 - 65 .
21. Abernethy AP, M cDonald C F, F rith P A, C lark K, Herndon JE 2nd, Marcello J. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: A double-blind, randomised controlled trial. Lancet 2010; 376 : 784 - 93 .
22. Philip J, G old M, M ilner A, D i Iulio J, M iller B, S pruyt O. A randomized, double-blind, crossover trial of the effect of oxygen on dyspnea in patients with advanced cancer. J Pain Symptom Manage 2006; 32 : 541 - 50 .
23. Bruera E, S weeney C, W illey J, P almer JL, S trasser F, Morice RC, et al. A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnea. Palliat Med 2003; 17 : 659 - 63 .
24. Booth S, K elly M J, C ox N P, A dams L, G uz A. D oes oxygen help dyspnea in patients with cancer? Am J Respir Crit Care Med 1996; 153 : 1515 - 8 .
25. Bruera E, d e Stoutz N, V elasco-Leiva A, S choeller T, Hanson J. Effects of oxygen on dyspnoea in hypoxaemic terminal-cancer patients. Lancet 1993; 342 : 13 - 4 .
26. Ahmedzai S H, L aude E, R obertson A, T roy G, V ora V. A double-blind, randomised, controlled phase II trial of Heliox28 gas mixture in lung cancer patients with dyspnoea on exertion. Br J Cancer 2004; 90 : 366 - 71 .
27. Navigante A H, C erchietti LC, C astro MA, L utteral MA, Cabalar ME. Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. J Pain Symptom Manage 2006; 31 : 38 - 47 .
28. Navigante AH, C astro M A, C erchietti L C. M orphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. J Pain Symptom Manage 2010; 39 : 820 - 30 .
29. Wilcock A, W alton A, M anderson C, F eathers L, El Khoury B, Lewis M, et al. Randomised, placebo controlled trial of nebulised furosemide for breathlessness in patients with cancer. Thorax 2008; 63 : 872 - 5 .
30. Stone P, K urowska A, T ookman A. N ebulized furosemide for dyspnoea. Palliat Med 1994; 8 : 258 .
31. Morgan JP. A merican opiophobia: Customary underutilisation of opioid analgesics. Adv Alcohol Subst Abuse 1985; 5 : 163 - 73 .
32. Bercovitch M, W aller A, A dunsky A. H igh dose morphine use in the hospice setting: A database survey of patient characteristics and effect on life expectancy. Cancer 1999; 86 : 871 - 7 .
33. Morita T, I chiki T, T sunoda J, I noue S, C hihara S. A prospective study on the dying process in terminally ill cancer patients. Am J Hosp Palliat Care 1998; 15 : 217 - 22 .
34. Morita T, T sunoda J, I noue S, C hihara S. E ffects of high dose opioids and sedatives on survival in terminally ill cancer patients. J Pain Symptom Manage 2001; 21 : 282 - 9 .
35. Grond S, Z ech D, S chug S A, L ynch J, L ehmann K A. V alidation of World Health Organisation guidelines for cancer pain relief during the last days and hours of life. J Pain Symptom Manage 1991; 6 : 411 - 22 .
36. Thorns A, S ykes N. O pioid use in the last week of life and implications for end of life decision-making. Lancet 2000; 356 : 398 - 9 .
37. Sykes N, T horns A. T he use of opioids and sedatives at the end of life. Lancet Oncol 2003; 4 : 312 - 8 .
38. A bernethy AP, C urrow DC, F rith P, F azekas BS, M cHugh A, Bui C. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003; 327 : 523 - 8 .
39. Escalante C P, M artin C G, E lting L S, C antor S B, H arle TS, Price KJ, et al. Dyspnea in cancer patients. Etiology, resource utilization, and survival-implications in a managed care world. Cancer 1996; 78 : 1314 - 9 .
40. Uronis HE, A bernethy A P. O xygen for relief of dyspnea: What is the evidence? Curr Opin Support Palliat Care 2008; 2 : 89 - 94 .
41. Currow DC, M cDonald C, O aten S, K enny B, A llcroft P, Frith P, et al. Once-daily opioids for chronic dyspnea: A dose increment and pharmacovigilance study. J Pain Symptom Manage 2011; 42 : 388 - 99 .
42. Reddy SK, P arsons HA, E lsayem A, P almer JL, B ruera E. Characteristics and correlates of dyspnea in patients with advanced cancer. J Palliat Med 2009; 12 : 29 - 36 .